Compare EXFY & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXFY | PYXS |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 166.6M |
| IPO Year | 2021 | 2021 |
| Metric | EXFY | PYXS |
|---|---|---|
| Price | $1.92 | $2.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.50 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 2.5M | 1.4M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,101,000.00 | $13,858,000.00 |
| Revenue This Year | $0.42 | N/A |
| Revenue Next Year | $0.11 | $7,043.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.06 | N/A |
| 52 Week Low | $0.69 | $0.97 |
| 52 Week High | $2.26 | $5.55 |
| Indicator | EXFY | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 67.39 | 56.09 |
| Support Level | $1.37 | $1.37 |
| Resistance Level | N/A | $2.92 |
| Average True Range (ATR) | 0.16 | 0.41 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 85.04 | 44.14 |
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app. Small and medium-sized businesses (SMBs) are the cornerstone of the global economy, making up almost all businesses and the majority of employment in Organization for Economic Co-operation and Development (OECD) member countries.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.